INTRODUCTION
============

Nearly three percent of the worldwide population has been infected with the hepatitis C virus (HCV) and about 80% of these cases are chronic.[@b1-gnl-10-456],[@b2-gnl-10-456] Chronic hepatitis C (CHC) infection has become one of the leading causes of liver-related mortality. Yet, the clinical progression of CHC-related liver diseases is highly variable.[@b3-gnl-10-456] Epidemiological studies have shown that the severity of liver disease in CHC is associated with older age, male gender, higher body mass index (BMI), insulin resistance, chronic alcohol consumption (\>30 to 50 g/day), viral factors (especially HCV genotype 3), or coinfection with human immunodeficiency virus.[@b4-gnl-10-456]--[@b8-gnl-10-456] However, even when combined these factors have an overall prediction rate of less than 30%.[@b9-gnl-10-456] Investigative research has turned to the influence of genetics.

Several potential genetic risk factors have been identified as having a key role in the severity of CHC-associated liver disease. The best documented is the polymorphism rs738409 (C\>G) of patatin-like phospholipase domain-containing protein 3 (*PNPLA3*), encoding the 148 isoleucine to methionine protein variant (p.I148M). Nevertheless, recognition of a correlation between *PNPLA3* rs73409 (C\>G) and the severity of liver steatosis or fibrosis in CHC has not reached a consensus. Several studies have indicated that CHC patients who carry the GG genotype of *PNPLA3* rs738409 (C\>G) are at high risk of advanced liver fibrosis,[@b10-gnl-10-456]--[@b12-gnl-10-456] but a similar result is not shown in others.[@b13-gnl-10-456] Moreover, among the studies that found a significant association the strength of the correlation varied, ranging from odds ratios (ORs) of 1.88[@b11-gnl-10-456] to 7.53[@b10-gnl-10-456] for advanced liver fibrosis, and 3.12[@b11-gnl-10-456] to 8.78[@b14-gnl-10-456] for liver steatosis.

By increasing the sample size, the objective of this meta-analysis was to explore more accurately the association between *PNPLA3* rs738409 (C\>G) and liver steatosis and advanced fibrosis in patients with CHC infection.

MATERIALS AND METHODS
=====================

1. Literature search and study selection
----------------------------------------

Relevant studies published before December 31, 2014 were found by searching the PubMed, Embase, and Web of Science databases, and the Google Scholar website for the query "(patatin-like phospholipase domain containing 3 or *PNPLA3*) and (rs738409 or I148M) and (fibrosis or steatosis) and (chronic hepatitis C or CHC or hepatitis C virus or HCV)." There were no language restrictions. Other potential sources were searched for in the references of qualified articles. Approval from the ethics committee was not required because we only used data that had been previously published. All study selection and data extraction was performed independently by two authors. Disagreements were resolved by discussion with a third author. A flow chart of the study selection process is shown in [Fig. 1](#f1-gnl-10-456){ref-type="fig"}.

2. Study inclusion and exclusion criteria
-----------------------------------------

The diagnosis of HCV infection in all patients of the selected studies was confirmed through serological examinations. Fibrosis and steatosis were confirmed by liver biopsy. Advanced fibrosis was defined as stage F3 (numerous septa without cirrhosis) or F4 (cirrhosis) according to the METAVIR score. The extent of steatosis was analyzed by calculating the percentage of lipid-containing hepatocytes in the total number of hepatocytes.

The selected studies conformed to the following criteria: (1) the studies focused on the polymorphism rs738409 (C\>G) of *PNPLA3* and fibrosis or steatosis in patients with CHC infection; (2) with sufficient reported data (stage of fibrosis or steatosis, and stratified outcomes according to *PNPLA3* genotype); (3) fit the diagnostic criteria for HCV infection, liver fibrosis and steatosis; and (4) the study was conducted in humans. If the same patient population was included in more than one study, the highest quality evaluation or the largest sample size was included. Letters, reviews or abstracts, and proceedings from clinical conferences were excluded.

3. Data extraction
------------------

The following data of each study was extracted independently by two authors: the first author, year of publication, ethnicity of subjects, age, BMI, gender ratio, HCV genotype, treatments, accompanying hepatitis B virus (HBV) or human immunodeficiency virus (HIV) infection, number of subjects, genotype frequencies of single nucleotide polymorphisms, and Hardy-Weinberg equilibrium (HWE). Results that were not reported directly were calculated from the data by two authors independently. Disagreements were resolved by discussion with a third author.

4. Quality assessment of the included studies
---------------------------------------------

Two authors independently assessed the quality of the included studies based on the Newcastle-Ottawa Scale (<http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp>).[@b15-gnl-10-456] The semi-quantitative star system, containing (selection, comparability, and exposure assessment) was applied. Disagreements were resolved by discussion with a third author.

5. Statistical analyses
-----------------------

The HWE of each study was tested using the chi-square test. Based on previous studies,[@b16-gnl-10-456] the ORs, and 95% confidence intervals (CIs) were calculated under the recessive genetic model (i.e., GG compared to CC+CG). The Z test and p\<0.05 were used to examine the statistical significance of the pooled ORs.

Cochran's Q-test and the I^2^ test were used to evaluate the heterogeneity between the studies.[@b17-gnl-10-456],[@b18-gnl-10-456] If p≥0.1 of the Q-test, or I^2^≤50%, we considered that no significant heterogeneity existed, so the fixed effects model (Mantel-Haenszel method) was used in this meta-analysis. If not, the random effects model (DerSimonian and Laird method) would be considered. A subgroup analysis by ethnicity or genotype of HCV was performed to find sources of heterogeneity.

Sensitivity was determined by repeating the analysis and evaluating the stability of each result, after omitting in turn the data of each study. To assess the potential publication bias, we used Begger's funnel plot and Egger's linear regression test.[@b19-gnl-10-456] Stata software for Windows version 12.0 (Stata, College Station, TX, USA) was used for all the statistical analyses.

RESULTS
=======

1. Characteristics of included studies
--------------------------------------

Five studies were relevant to advanced fibrosis of the liver in CHC and comprised 2,037 patients. There were no statistically significant differences among them with regard to age, BMI, or gender ratio (specific data are not listed), including 651 patients with advanced fibrosis (METAVIR stages F3--F4). In four of these the subjects were Caucasian, and in one the subjects were Asian ([Table 1](#t1-gnl-10-456){ref-type="table"}). The four studies with Caucasian subjects also concerned steatosis of the liver with, in total, 694 subjects in whom the extent of steatosis was more than 5%. All of the patients had performed liver biopsies before received the treatment of pegylated interferon and ribavirin, and were without HBV or HIV infection.

Based on the results of the line probe assay VERSANT HCV Genotype 2.0 (Siemens, Tarrytown, NY, USA), two studies[@b10-gnl-10-456],[@b12-gnl-10-456] included patients infected with the HCV genotypes 1 or 4; in one study,[@b13-gnl-10-456] patients were infected with HCV genotypes 1 or 2; and in the remaining two studies,[@b11-gnl-10-456],[@b14-gnl-10-456] patients were infected with HCV genotypes 1, 2, 3, or 4. The genotyping of *PNPLA3* (rs738409) was performed using the TaqMan Assay (Applied Biosystems, Foster City, CA, USA). After calculation, all allele frequencies were in HWE (p\>0.05).

2. Association between *PNPLA3* rs738409 (C\>G) and advanced fibrosis
---------------------------------------------------------------------

With regard to the association between *PNPLA3* rs738409 (C\>G) and advanced fibrosis in CHC patients, in this meta-analysis interstudy heterogeneity was found, but was not significant (I^2^=37.7%, p=0.170); therefore the fixed effects model (Mantel-Haenszel method) was used to calculate the pooled OR and 95% CI. The genotype GG of *PNPLA3* rs738409 (C\>G) was associated with higher risk of advanced liver fibrosis in patients with CHC (GG versus CC+CG: OR, 2.19; 95% CI, 1.59 to 3.02; p\<0.05) ([Fig. 2A](#f2-gnl-10-456){ref-type="fig"}).

The subgroup analysis by ethnicity showed that in the Caucasian populations, CHC patients with genotype GG had a higher risk of advanced fibrosis of the liver compared with those with genotype CC+CG (OR, 2.51; 95% CI, 1.75 to 3.60; p\<0.05). However, this association was not observed in the Asian population (OR, 1.31; 95% CI, 0.65 to 2.67; p=0.457).

We further performed a subgroup analysis based on HCV genotype in Caucasians. Subgroup A included two studies[@b10-gnl-10-456],[@b12-gnl-10-456] in which the CHC patients were infected with HCV-1 or HCV-4 only. Subgroup B included the other two studies[@b11-gnl-10-456],[@b14-gnl-10-456] comprising CHC patients infected with not only HCV-1 or HCV-4 but also HCV-2 or HCV-3. Although the two subgroups differed, the difference was not significant (subgroup A: OR, 3.57; 95% CI, 1.90 to 6.69; subgroup B: OR, 2.11; 95% CI, 1.35 to 3.29; p=0.17) ([Fig. 2B](#f2-gnl-10-456){ref-type="fig"}).

3. Association between *PNPLA3* rs738409 (C\>G) and steatosis
-------------------------------------------------------------

With regard to the association between *PNPLA3* rs738409 (C\>G) polymorphism and steatosis in CHC patients, in this meta-analysis interstudy heterogeneity was not observed (I^2^=0.0%, p=0.658), and therefore the fixed effects model (Mantel-Haenszel method) was used to calculate the pooled OR and 95% CI. The genotype GG of *PNPLA3* rs738409 (C\>G) was associated with the risk of steatosis of the liver in patients with CHC (GG versus CC+CG: OR, 4.33; 95% CI, 2.59 to 7.22; p\<0.05) ([Fig. 3](#f3-gnl-10-456){ref-type="fig"}).

We also performed a subgroup analysis stratified by HCV genotype, whereby in subgroup A, the CHC patients were infected with HCV-1 or HCV-4 only,[@b10-gnl-10-456],[@b12-gnl-10-456] and in subgroup B, the CHC patients were infected with HCV-1, 2, 3, or 4.[@b11-gnl-10-456],[@b14-gnl-10-456] Although the two subgroups differed, the difference was not significant (subgroup A: OR, 6.20; 95% CI, 2.16 to 17.79; subgroup B: OR, 3.79; 95% CI, 2.11 to 6.68; p=0.49).

4. Sensitivity analysis
-----------------------

For the sensitivity analysis we used the random effects model to recalculate the pooled ORs (95% CIs), and there were no significant changes in results. Furthermore, when any single study was deleted, the corresponding pooled ORs were not substantially altered ([Fig. 4](#f4-gnl-10-456){ref-type="fig"}), suggesting that the results of this meta-analysis were stable.

5. Publication bias
-------------------

Begger's funnel plots ([Fig. 5](#f5-gnl-10-456){ref-type="fig"}) and Egger's linear regression test were performed to assess the publication bias of all included studies. The results indicated no evidence of publication bias (advanced fibrosis, p=0.144; steatosis, p=0.504).

6. Quality assessment
---------------------

Based on the Newcastle-Ottawa Scale, the quality evaluations of the included studies showed that all five of the included studies earned more than five stars, and therefore could be considered medium-high quality reports ([Table 2](#t2-gnl-10-456){ref-type="table"}). Disagreements were also resolved by discussion with a third author.

DISCUSSION
==========

This meta-analysis investigated whether the *PNPLA3* polymorphism rs738409 (C\>G) is related to liver steatosis or advanced fibrosis in CHC patients. We conducted a search for relevant papers published up to June 1, 2014 in the PubMed, Embase, Web of Science, and Google Scholar databases, as well as the papers cited in these articles. Five studies satisfied the inclusion criteria, in which the cohorts of four were Caucasians, and in one the subjects were Asian. It was determined that *PNPLA3* rs738409 (C\>G) was associated with risk of both advanced liver fibrosis and steatosis in patients with CHC. The association was especially strong among Caucasians.

*PNPLA3* rs738409 (C\>G) was previously revealed as a major determinant of steatosis in nonalcoholic fatty liver disease,[@b20-gnl-10-456]--[@b22-gnl-10-456] and associated with advanced disease course in alcoholic liver disease.[@b23-gnl-10-456]--[@b25-gnl-10-456] However, in CHC, there is still no definitive consensus. This may be explained by differences in sample size, ethnicity, HCV genotype, or HWE.[@b26-gnl-10-456]--[@b28-gnl-10-456] In the present meta-analysis, the pooled results of all five studies showed that the genotype GG of *PNPLA3* rs738409 (C\>G) was associated with a higher risk of both advanced liver fibrosis and liver steatosis compared with CC or CG in CHC patients. Subgroup analysis found that the association with advanced liver fibrosis was stronger among Caucasian populations than Asian populations, although there were no statistically significant differences among them regarding age, BMI, or gender ratio. This result may be related to the interleukin-28B (*IL28B*) gene polymorphism, which has been confirmed as another factor associated with the severity of liver disease in CHC.[@b29-gnl-10-456]

A previous study observed that *IL28B*-CC protected *PNPLA3*-GG patients from steatosis, and in several studies the Asian population had a higher frequency of the favorable *IL28B*-CC genotype than Caucasians.[@b30-gnl-10-456]--[@b32-gnl-10-456] Perhaps the same is true for fibrosis liver disease. More related research is needed to reveal the detailed mechanism.

We also stratified the subjects according to HCV genotype. The genotype GG of *PNPLA3* rs738409 (C\>G) increased the risk of advanced liver fibrosis and liver steatosis, no matter the infecting HCV genotype (HCV-1 and HCV-4 versus HCV-1, 2, 3, and 4). Although the risk of advanced liver fibrosis and liver steatosis in CHC patients infected with HCV-1 or HCV-4 was higher than in those infected with HCV-2 or HCV-3 as well, the difference was not significantly different. This may be because the numbers in the second group were comparatively few. The patients of all these studies were native Caucasians, and in Caucasians, HCV-1 (especially HCV-1b) was found previously to be the most prevalent genotype.[@b33-gnl-10-456] In each of the studies included in the present analysis, the proportion of patients infected with HCV-1 was more than 60%. Thus, the proportion of patients infected with HCV-2 or HCV-3 was too small to influence this result. Studies with a greater number of patients infected with HCV-2 or -3 are needed if we want to reveal more accurately the association between the *PNPLA3* rs738409 (C\>G) polymorphism and HCV genotype in liver disease progression of CHC.

This is the first meta-analysis concerning the relatedness of the *PNPLA3* rs738409 (C\>G) polymorphism and liver disease susceptibility in patients with CHC. Meta-analysis has become a new tool in genetic epidemiology and has been widely used, because it can enlarge the sample size and subsequently enhance the statistical power of quantitative analysis, to obtain more reliable conclusions.[@b34-gnl-10-456] Before initiating this meta-analysis, we ensured that it was well designed with explicit methods for study selection, data extraction, and data analysis, and the quality of the included studies were all found sufficient ([Table 2](#t2-gnl-10-456){ref-type="table"}). No evidence of publication bias was detected, and the sensitivity analysis indicated that the results of the meta-analysis were stable.

This meta-analysis is limited in that only five studies were included, and therefore the sample size and statistical power may be insufficient. As more original studies are performed that investigate the association between *PNPLA3* rs738409 (C\>G) and liver disease susceptibility in patients with CHC, data should be pooled to update this meta-analysis, especially for Asian populations or other ethnic groups. Furthermore, our lack of access to the original data of the studies limited further evaluations of the potential effects of the polymorphism on liver disease susceptibility. For example, from the articles there is no unified standard of diagnostic criteria or grading system for fibrosis and steatosis. Finally, although no publication bias was found by statistical analysis, this may have occurred since only published studies were included in the meta-analysis.

In conclusion, the results of this meta-analysis indicate that the genotype GG of *PNPLA3* rs738409 (C\>G) was associated with a higher risk of both advanced liver fibrosis and liver steatosis in patients with CHC, and especially among Caucasian compared with Asian cohorts. More research should be conducted to reveal how the *PNPLA3* rs738409 (C\>G) polymorphism and different ethnic, *IL28B*, or HCV genotypes are related in liver disease progression of CHC. This meta-analysis should be updated continually.
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![Schematic of the study selection process. HCV, hepatitis C virus.](gnl-10-456f1){#f1-gnl-10-456}

![Advanced fibrosis. Summary estimates for odds ratios (ORs, effect), the corresponding 95% confidence interval (CI) limits (lower and upper), percent weight, and overall or subtotal (I^2^ and p-value) were calculated by fixed effects meta-analysis for advanced fibrosis. The first author of the study and the year of publication are shown. (A) The forest plots of all five studies were relevant to advanced fibrosis and the subgroup analysis by ethnicity. (B) The forest plots of all five studies were relevant to advanced fibrosis and the subgroup analysis based on hepatitis C virus (HCV) genotype.](gnl-10-456f2){#f2-gnl-10-456}

![Liver steatosis. Summary estimates for odds ratios (ORs, effect), the corresponding 95% confidence interval (CI) limits (lower and upper), percent weight, and overall or subtotal (I^2^ and p-value) were calculated by fixed effects meta-analysis for liver steatosis. The forest plots of all five studies were relevant to liver steatosis and the subgroup analysis based on hepatitis C virus (HCV) genotype.](gnl-10-456f3){#f3-gnl-10-456}

![Sensitivity analysis of the summary odds ratio. The results were computed by omitting each study in turn. Meta-analysis random effects estimates (exponential form) were used. The two ends of the dotted lines represent the 95% confidence interval. (A) Association between patatin-like phospholipase domain-containing protein 3 (*PNPLA3*) rs738409 single nucleotide polymorphism (SNP) and advanced fibrosis. (B) Association between *PNPLA3* rs738409 SNP and liver steatosis.](gnl-10-456f4){#f4-gnl-10-456}

![Begger's funnel plot. Each point represents a separate study for the indicated association. Horizontal line means magnitude of the effect. (A) Association between patatin-like phospholipase domain-containing protein 3 (*PNPLA3*) rs738409 single nucleotide polymorphisms (SNP) and advanced fibrosis. (B) Association between *PNPLA3* rs738409 SNP and liver steatosis. s.e., standard error; LogOR, natural logarithm of odds ratio.](gnl-10-456f5){#f5-gnl-10-456}

###### 

Characteristics of the Cohorts of the Included Studies[\*](#tfn2-gnl-10-456){ref-type="table-fn"}

  Author (year)                                   Ethnicity   HCV genotype   Fibrosis   Steatosis   HWE                                         
  ----------------------------------------------- ----------- -------------- ---------- ----------- ----- -------- ----- ------- ----- -------- ------
  Stattermayer *et al*. (2012)[@b10-gnl-10-456]   Caucasian   1, 4           159        155/4       43    36/7     87    85/2    115   106/9    0.56
  Valenti *et al*. (2012)[@b11-gnl-10-456]        Caucasian   1, 2, 3, 4     423        395/28      179   158/21   196   189/7   406   364/42   0.44
  Stattermayer *et al*. (2013)[@b12-gnl-10-456]   Caucasian   1, 4           322        308/14      156   138/18   147   145/2   213   190/23   0.69
  Trepo *et al*. (2011)[@b14-gnl-10-456]          Caucasian   1, 2, 3, 4     321        306/15      216   193/23   264   257/7   273   242/31   0.92
  Miyashita *et al*. (2012)[@b13-gnl-10-456]      Asian       1, 2           161        129/32      57    43/14    \-    \-      \-    \-       0.59

HCV, hepatitis C virus; HWE, Hardy-Weinberg equilibrium.

All studies were in HWE.

###### 

Quality of the Included Studies

  Author (year)                                   Selection   Comparability   Exposure/outcome
  ----------------------------------------------- ----------- --------------- ------------------
  Stattermayer *et al*. (2012)[@b10-gnl-10-456]   ★★★         ★★              ★★★
  Valenti *et al*. (2012)[@b11-gnl-10-456]        ★★          ★★              ★★★
  Stattermayer *et al*. (2013)[@b12-gnl-10-456]   ★★★         ★★              ★★★
  Trepo *et al*. (2011)[@b14-gnl-10-456]          ★★          ★★              ★★★
  Miyashita *et al*. (2012)[@b13-gnl-10-456]      ★★★         ★★              ★★
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